Full Press Release Details
Preclinical Data Demonstrates Potential Of Eidos Therapeutics' Lead Compound For The Treatment For Transthyretin Amyloidosis.
BBIO
Preclinical Data Demonstrates Potential Of Eidos Therapeutics' Lead Compound For The Treatment For Transthyretin Amyloidosis
Key Takeaway: Preclinical Data Demonstrates Potential Of Eidos Therapeutics' Lead Compound For The Treatment For Transthyretin Amyloidosis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis